Ascendis Pharma (ASND) Q1 2024: Skytrofa Revenue Doubles, Lifts Path to Cash Flow Breakeven

2024-05-02 | By EarningsIQ Research

Ascendis Pharma’s Q1 marked a pivotal inflection, with Skytrofa’s demand-driven 106% revenue surge driving the company toward quarterly cash flow breakeven by year-end. Early Yorvipath adoption in Europe exceeded expectations, validating the commercial model for upcoming launches. With critical regulatory milestones and pipeline catalysts ahead, execution and cost discipline remain central to the Ascendis investment case.

Summary

• Skytrofa Outpaces Market: Only growth hormone therapy to post value growth in a challenging quarter.
• Yorvipath Launch Validates Model: Rapid prescriber uptake in Germany and Austria signals strong demand for new indications.
• Cash Flow Breakeven in Sight: Cost discipline and operating leverage underpin breakeven target by end of 2024.

Business Overview

Ascendis Pharma is a biopharmaceutical company leveraging its proprietary TransCon platform, a sustained-release drug technology, to develop and commercialize therapies for rare endocrine diseases, oncology, and metabolic disorders. The company’s core commercial products are Skytrofa (TransCon Growth Hormone) for pediatric growth hormone deficiency and Yorvipath (TransCon PTH) for chronic hypoparathyroidism, with a robust pipeline including TransCon CNP for achondroplasia and several oncology assets. Revenue is primarily generated from product sales in the U.S. and Europe, with additional contributions from licensing and service agreements.

Performance Analysis

Ascendis delivered a transformative quarter, with Skytrofa revenue up 106% year over year, propelled by strong demand volume and continued patient adds. Notably, Skytrofa was the only product in the U.S. growth hormone market to post value growth in Q1, as peers saw declines. Yorvipath’s European launch contributed its first revenue, with direct-to-pharmacy sales in Germany and Austria and no channel inventory buildup, a model that enhances launch visibility and reduces working capital drag.

Operating leverage was clear: total operating expenses fell 20% year over year, driven by a 33% reduction in R&D costs as legacy trial expenses rolled off and pipeline investment shifted to late-stage programs. SG&A was held flat despite commercial expansion, reflecting the benefits of last year’s streamlining. Operating loss narrowed sharply, even as finance expense spiked due to IFRS-driven, non-cash convertible note reclassification.

• Demand-Driven Revenue Surge: Skytrofa’s patient growth and market penetration drove the topline, with volume more than doubling year over year.
• Expense Discipline: R&D and total operating expenses declined materially, supporting the path to breakeven.
• Channel Inventory Management: Yorvipath’s direct-to-pharmacy model in Europe avoids U.S.-style channel build, reducing launch risk.

Ascendis ended the quarter with €320 million in cash and reiterated its full-year guidance for Skytrofa and operating expenses, maintaining confidence in achieving operating cash flow breakeven by year-end.

Executive Commentary

Strategic Positioning

1. Skytrofa: Expanding Leadership in Growth Hormone Deficiency

Skytrofa, once-weekly growth hormone therapy, continues to consolidate its position as the value leader in pediatric growth hormone deficiency. With penetration now at 17% of the U.S. market and the only product to post value growth in Q1, management expects further share gains as daily injectables exit and adult indications come online. The adult growth hormone deficiency sBLA is scheduled for Q3 submission, and Turner Syndrome data is expected in Q4.

2. Yorvipath: Early Validation in European Launch

Yorvipath, once-daily parathyroid hormone replacement, launched in Germany and Austria with rapid adoption: 25% of target prescribers wrote scripts within eight weeks, and 100 patients initiated therapy, many of whom were treatment-naïve. This suggests significant untapped demand and positions Ascendis to replicate the launch playbook across Europe and, pending U.S. approval, in America later this year.

3. Pipeline Execution and Platform Leverage

TransCon CNP is advancing toward a pivotal data readout in Q3 for achondroplasia, with a focus on addressing comorbidities beyond linear growth. Oncology programs (TransCon IL-2 beta gamma, TransCon TLR-7-8 agonist) are progressing, with updated data expected at ASCO and additional readouts in Q4. The TransCon carrier platform’s expansion into metabolic disease (GLP-1) is ongoing, with strategic options under review.

4. Commercial Infrastructure and Market Access

Ascendis is leveraging a dual commercial infrastructure in Europe and the U.S., with independent sales forces targeting highly specialized prescribers. The company is emphasizing health economic modeling and real-world value to support pricing and reimbursement, particularly in Europe’s cost-conscious markets.

Key Considerations

This quarter’s results reinforce Ascendis’s ability to deliver commercial growth while maintaining cost discipline, a rare combination in emerging biopharma. Investors should weigh the following:

Key Considerations:

• Execution on Upcoming Launches: Yorvipath’s U.S. launch (pending FDA approval) and further European rollout are critical to sustaining momentum.
• Pipeline Catalysts: Multiple data readouts and regulatory filings in growth disorders and oncology will shape the long-term value proposition.
• Operating Leverage: The ability to hold expenses flat or declining while scaling revenue is central to the breakeven target.
• Market Dynamics: The consolidation of daily growth hormone therapies and unmet needs in hypoparathyroidism create tailwinds, but also raise competitive stakes for innovation and access.

Risks

Key risks include regulatory delays or setbacks, particularly for Yorvipath’s U.S. approval, and potential payer pushback on pricing or access in both the U.S. and Europe. Pipeline readouts in achondroplasia and oncology carry scientific and commercial risk. Non-cash finance expense volatility tied to convertible notes under IFRS is not operationally material but could cloud headline results. Any slowdown in Skytrofa demand or failure to execute on new launches would challenge the breakeven narrative.

Forward Outlook

For Q2 2024, Ascendis expects:

• Skytrofa revenue momentum to continue, with seasonal headwinds now behind.
• Ongoing European expansion of Yorvipath and pre-launch U.S. activities pending May 14 PDUFA.

For full-year 2024, management maintained guidance:

• Skytrofa revenue of €340 million at 2023 exchange rates.
• Total operating expenses (SG&A plus R&D) of approximately €600 million.
• Operating cash flow breakeven on a quarterly basis by year-end.

Management highlighted several factors that will influence results:

• Progress of regulatory reviews and launches for Yorvipath and pipeline assets.
• Ability to maintain cost discipline and realize operating leverage as commercial scale increases.

Takeaways

Ascendis’s Q1 2024 results highlight a business at a strategic crossroads, with commercial momentum, cost control, and pipeline execution converging to set up a pivotal year.

• Commercial Flywheel: Skytrofa’s continued outperformance and Yorvipath’s early European success provide a template for future launches and margin expansion.
• Disciplined Growth: The company’s ability to reduce operating expenses while scaling revenue is a key differentiator versus peers.
• Upcoming Catalysts: Investors should watch for U.S. Yorvipath approval, TransCon CNP pivotal data, and further European launches as critical drivers for the next phase of value creation.

Conclusion

Ascendis Pharma’s Q1 confirmed the commercial and operational thesis underpinning its Vision 2030 strategy. With Skytrofa’s blockbuster trajectory, Yorvipath’s launch validation, and disciplined cost management, the company is positioned to deliver on its promise of sustainable growth and operating cash flow breakeven by year-end.

Industry Read-Through

Ascendis’s results signal a broader shift in rare disease biopharma toward commercial discipline and platform leverage. The company’s dual-market launch strategy and focus on health economic value are increasingly critical as payers scrutinize new therapies. Skytrofa’s outperformance in a consolidating growth hormone market highlights the value of differentiated, long-acting therapies, while Yorvipath’s rapid adoption demonstrates latent demand for innovation in endocrinology. For peers, the bar for launch execution and cost control is rising, and the ability to scale commercial infrastructure without margin erosion will separate long-term winners from laggards.

ASND Healthcare Biotechnology Rare Disease Endocrinology Commercialization Pipeline Skytrofa